Table 1.
Clinical and epidemiological baseline characteristics of the study cohort.
| Title | Experimental (n = 15) | Control (n = 14) | Total (n = 29) | p- value |
|---|---|---|---|---|
| Age, years | 45 (36–52) | 44 (35–45) | 44 (36–48) | 0.373 |
| Male | 12 (80) | 13 (87) | 25 (83) | 1 |
| BMI, kg/m2 | 23.9 (21.5–24.8) | 22.7 (20.9–24.4] | 23.8 (21.5–24.6] | 0.361 |
| Race/ethnicity | 0.597 | |||
| Hispanic | 1 (7) | 3 (20) | 4 (13) | |
| Caucasian | 13 (87) | 12 (80) | 25 (83) | |
| African | 1 (7) | 0 (0) | 1 (3) | |
| Current smoker | 6 (40) | 5 (33) | 11 (37) | 0.705 |
| HIV infection, years | 10 (7–13) | 9 (7–16) | 10 (7–15) | 0.604 |
| HIV risk factor | 1 | |||
| Heterosexual | 4 (27) | 4 (27) | 8 (27) | |
| MSM | 10 (67) | 9 (60) | 19 (63) | |
| Injection drug abuse | 0 (0) | 1 (7) | 1 (3) | |
| Other | 1 (7) | 1 (7) | 1 (3) | |
| Prior AIDS | 3 (20) | 1 (7) | 4 (13) | 0.598 |
| Time on ART, years | 7 (4–13) | 8 (5–16) | 7 (5–14) | 0.330 |
| Time on EFV/FTC/TDF, years | 6 (4–8) | 6 (4–9) | 6 (4–8) | 0.756 |
| Nadir CD4+ count, cells/µL | 224 (109–400) | 240 (168–365) | 236 (139–390) | 0.576 |
| Current CD4+ count, cells/µL | 730 (560–950) | 740 (540–1000) | 740 (540–950) | 0.678 |
| Current CD8+ count, cells/µL | 675 (510–760) | 630 (490–830) | 660 (510–820) | 0.861 |
| Lipid parameters | ||||
| TC, mg/dL | 214 (189–240) | 200 (184–226) | 207 (185–234) | 0.175 |
| LDL-c, mg/dL | 137 (122–157) | 126 (93–147) | 133 (96–151) | 0.141 |
| HDL-c, mg/dL | 58 (40–64) | 54 (41–64) | 57 (41–64) | 0.927 |
| Triglycerides, mg/dL | 122 (103–141] | 115 (87–166) | 117 (100–152) | 0.646 |
| apoA, g/dL | 149 (140–178] | 150 (128–172) | 149 (133–172) | 0.468 |
| apoB, g/dL | 94 (83–108] | 88 (70–100) | 91 (74–103) | 0.340 |
| Other laboratory parameters | ||||
| ALT, UI/L | 29 (22–38] | 23 (20–31) | 23 (21–32) | 0.197 |
| ALP, UI/L | 116 (80–135] | 94.50 (84–134) | 98 (80–134) | 0.854 |
| AST, UI/L | 22 (20–32] | 24 (20–27) | 23 (20–28) | 0.729 |
| Bilirubin, mg/dL | 0.42 (0.35–0.52] | 0.35 (0.27–0.39) | 0.38 (0.33–0.47) | 0.135 |
| GGT, UI/L | 53 (37–61] | 36 (28–66) | 45 (31–63) | 0.141 |
| Glucose, mg/dL | 92 (83–100] | 89 (83–90) | 90 (83–99) | 0.596 |
| Insulin, mU/L | 15.0 (10.4–17.8) | 11.6 (7.6–28.1) | 14.2 (9.3–22.7) | 0.604 |
| Total protein, g/dL | 7.20 (7.00–7.60) | 7.20 (7.00–7.50) | 7.20 (7.00–7.55) | 0.854 |
Data are presented as n (%) or median (interquartile range). Categorical data were compared by means of a χ2 test, whereas continuous data were compared using nonparametric Mann-Whitney test. BMI: Body Mass Index; MSM: men who have sex with men; ART: antiretroviral treatment; EFV: efavirenz; FTC: emtricitabine; TDF: tenofovir disoproxil fumarate; TC: total cholesterol; LDL-c: low-density lipoprotein cholesterol; HDL-c: high-density lipoprotein cholesterol; apoA: Apolipoprotein A; apoB: Apolipoprotein B; ALT: alanine aminotransferase; ALP: Alkaline phosphatase; AST: Aspartate aminotransferase; GGT: Gama-glutamyl transferase.